2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management, and Key Considerations During the COVID-19 Era

Thank you for joining!


Check out a replay of the event here:

Twitter:  https://twitter.com/NeuroForuMS/status/1451321210822963209?s=20

Facebook: https://fb.watch/8OMZ8DOCG3/

YouTube: https://youtu.be/35s7pwnTkKY


Claim credit: https://bit.ly/3m1Sd5Z




Although the multifactorial causes of multiple sclerosis (MS) are not known, an improved understanding of the neuroimmunologic pathogenesis has led to the development of a wide variety of disease-modifying treatments (DMTs). While there is no cure for MS, these treatments can reduce disease activity and delay MS progression and disability.

However, having more DMT options than ever, and more still in clinical development, further complicates treating an already complex condition. With a wide variety of mechanisms of action (MOAs), selecting the optimal DMT is a formidable challenge with the opportunity to improve short-and long-term outcomes. Yet, using a treatment that is unsuitable to the patient’s individual disease activity, prognosis, and preferences is likely to lead to intolerable adverse events (AEs) and nonadherence. Given an MS patient’s immunosuppressed status and increased risk of infection. Adherence issues are further compounded during the pandemic as a result of stay-at-home orders.

Personalized treatment incorporates patient preferences for selecting, starting, switching, and stopping therapies as the patient’s circumstances change, as the disease progresses, and as the patient ages. Parsing the therapeutic alternatives can yield the most benefit when an interdisciplinary shared decision-making (SDM) approach is used.MS is a therapeutic area that is rapidly evolving and neurology clinicians need to remain updated on emerging therapies,

Through this initiative, participants will gain the knowledge and competence to develop early, aggressive plans that balance the benefits and risks of MS treatment options in order to optimize patient management through SDM.


Aaron Boster, MD
Founder and President
The Boster Center for Multiple Sclerosis
Columbus, Ohio


Mitzi Joi Williams, MD
Medical Director and CEO
Joi Life Wellness Group
Atlanta, Georgia


This program is intended for MS specialists, neurologists, internists, nurse practitioners, and physician assistants who are involved in the care of patients with MS.


Upon completion of this educational activity, participants should be able to:

  • Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS
  • Personalize treatment selection when starting, switching, or stopping a pharmacologic based on efficacy, safety, and patient preference
  • Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS
  • Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS
  • Identify up-to-date recommendations for patients with MS during COVID-19 era including registries and treatment considerations


There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the live broadcast
  • Complete the posttest evaluation form at the end of the program

Your certificate will be sent to you within four weeks of receipt of the completed evaluation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme, Novartis
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme
Institution Research Grants: AbbVie, Alkermes, Bayer, Biogen, MedImmune, Novartis, Roche, Sanofi Genzyme

Mitzi Joi Williams, MD
Consulting Fees: AbbVie, Alexion, Biogen, Bristol Myers Squibb, Biogen, EMD Serono, Genentech, Genzyme, Janssen, Novartis
Speakers’ Bureaus: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis

 Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  •  Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


This activity is supported by an independent educational grant from Biogen.



On the day of the program, you may access the event by going to any of the following links:

Twitter:  https://twitter.com/NeuroForuMS

Facebook: https://www.facebook.com/integritycontinuingeducation

YouTube: https://www.youtube.com/channel/UC7YBDn98MBWpxHIP79JqShg

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 0.75 AMA PRA Category 1 CME credit(s)TM. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within 30 days of the activity and submission of a completed activity evaluation form.